---
title: "BrightGene terminates the review of stock issuance to specific objects"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/261836099.md"
description: "BrightGene Bio-Medical Technology Co., Ltd. decided to terminate the issuance of A-shares to specific targets for the year 2024 at the 13th meeting of the 4th Board of Directors and has withdrawn the application documents. The company and its sponsor, Guolian Minsheng Securities, have submitted a withdrawal application to the Shanghai Stock Exchange and received the decision from the Shanghai Stock Exchange on October 21, terminating the review of its stock issuance"
datetime: "2025-10-20T08:35:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261836099.md)
  - [en](https://longbridge.com/en/news/261836099.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261836099.md)
generator: "portal-rs"
---

# BrightGene terminates the review of stock issuance to specific objects

In 2025, BrightGene Bio-Medical Technology Co., Ltd. held the 13th meeting of the fourth board of directors, where it reviewed and approved the proposal to terminate the issuance of A-shares to specific targets for the year 2024 and to withdraw the application documents, with related director Yuan Jiandong abstaining from the vote. Subsequently, the company and its sponsor, Guolian Minsheng Securities Co., Ltd., submitted an application to the Shanghai Stock Exchange to withdraw the application documents and revoke the sponsorship work. On October 21, the company announced that it had previously received the Shanghai Stock Exchange's decision to terminate the review of BrightGene Bio-Medical Technology Co., Ltd.'s issuance of stocks to specific targets, based on relevant regulations

### Related Stocks

- [688166.CN](https://longbridge.com/en/quote/688166.CN.md)

## Related News & Research

- [Butler National Wins Three-Year Extension to Manage Kansas Sports Wagering, Retains 90% Revenue Share](https://longbridge.com/en/news/296516585.md)
- [Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78](https://longbridge.com/en/news/296368941.md)
- [Earth Science Tech (ETST) Continues Steady Growth with Acquisition of California-Based Compounding Pharmacy](https://longbridge.com/en/news/296513181.md)
- [Waga Energy commissions Decatur Hills landfill RNG unit in Indiana](https://longbridge.com/en/news/296252697.md)
- [Viva Gold targets 2027 start for NEPA mine permitting at Tonopah project in Nevada](https://longbridge.com/en/news/296094677.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**